{"classes":[{"categories":[{"measurements":[{"comment":"95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"6.7"},{"comment":"95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"3.5"},{"comment":"Upper limit of 95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG002","lowerLimit":"1.2","upperLimit":"NA","value":"1.3"},{"comment":"Upper limit of 95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG003","lowerLimit":"1.1","upperLimit":"NA","value":"5.3"},{"comment":"Upper limit of 95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG004","lowerLimit":"1.4","upperLimit":"NA","value":"2.8"},{"comment":"Upper limit of 95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG005","lowerLimit":"0.7","upperLimit":"NA","value":"2.6"},{"comment":"Median and 95% confidence interval were not reached due to an insufficient events being observed.","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"1.6"},{"comment":"Upper limit of 95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG008","lowerLimit":"1.3","upperLimit":"NA","value":"1.6"},{"comment":"Upper limit of 95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG009","lowerLimit":"1.0","upperLimit":"NA","value":"4.3"},{"comment":"Upper limit of 95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG010","lowerLimit":"0.4","upperLimit":"NA","value":"0.8"},{"groupId":"OG011","lowerLimit":"1.2","upperLimit":"2.8","value":"2.6"},{"groupId":"OG012","lowerLimit":"1.2","upperLimit":"3.9","value":"2.6"},{"groupId":"OG013","lowerLimit":"1.3","upperLimit":"5.0","value":"2.8"},{"groupId":"OG014","lowerLimit":"1.4","upperLimit":"4.1","value":"2.6"},{"groupId":"OG015","lowerLimit":"1.6","upperLimit":"2.1","value":"1.9"},{"groupId":"OG016","lowerLimit":"1.3","upperLimit":"3.0","value":"1.6"},{"groupId":"OG017","lowerLimit":"1.4","upperLimit":"3.9","value":"2.2"},{"groupId":"OG018","lowerLimit":"1.1","upperLimit":"4.0","value":"2.6"},{"groupId":"OG019","lowerLimit":"1.4","upperLimit":"4.1","value":"2.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"22"},{"groupId":"OG012","value":"16"},{"groupId":"OG013","value":"25"},{"groupId":"OG014","value":"25"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"25"},{"groupId":"OG017","value":"55"},{"groupId":"OG018","value":"21"},{"groupId":"OG019","value":"26"}],"units":"Participants"}],"description":"The PFS was defined as the number of months from the date of first study drug administration to first PD or death. The PD was defined as at least 20% increase in the sum of longest diameters of target lesions taking as reference the smallest sum of the longest diameters recorded since the treatment started or the appearance of one or more new lesions. The PFS was estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.3 mg/kg 1Q3W until the end of treatment.","id":"OG000","title":"Dose-escalation Part: Enapotamab Vedotin 0.3 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 1Q3W until the end of treatment.","id":"OG001","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 1Q3W until the end of treatment.","id":"OG002","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.5 mg/kg 1Q3W until the end of treatment.","id":"OG003","title":"Dose-escalation Part: Enapotamab Vedotin 1.5 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.0 mg/kg 1Q3W until the end of treatment.","id":"OG004","title":"Dose-escalation Part: Enapotamab Vedotin 2.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG005","title":"Dose-escalation Part: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.4 mg/kg 1Q3W until the end of treatment.","id":"OG006","title":"Dose-escalation Part: Enapotamab Vedotin 2.4 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 3Q4W until the end of treatment.","id":"OG007","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.8 mg/kg 3Q4W until the end of treatment.","id":"OG008","title":"Dose-escalation Part: Enapotamab Vedotin 0.8 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"OG009","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.2 mg/kg 3Q4W until the end of treatment.","id":"OG010","title":"Dose-escalation Part: Enapotamab Vedotin 1.2 mg/kg 3Q4W"},{"description":"Participants with advanced and/or metastatic NSCLC with classical sensitizing EGFR mutations and/or EGFR mutations targeted by third-generation tyrosine kinase inhibitors) received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG011","title":"Expansion Part Cohort 1: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic melanoma with BRAF V600 mutation received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG012","title":"Expansion Part Cohort 3: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic melanoma with BRAF V600 wild type received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG013","title":"Expansion Part Cohort 4: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic sarcoma received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG014","title":"Expansion Part Cohort 5: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic solid tumors (excluding NSCLC, melanoma, sarcoma, and ovarian cancer unless having a known AXL gene amplification) received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"OG015","title":"Expansion Part Cohort 6: Enapotamab Vedotin 1.0 mg/kg 3Q4W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG016","title":"Expansion Part Cohort 7: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG017","title":"Expansion Part Cohort 2: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 1.8 mg/kg 1Q3W until the end of treatment.","id":"OG018","title":"Expansion Part Cohort 2: Enapotamab Vedotin 1.8 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"OG019","title":"Expansion Part Cohort 8: Enapotamab Vedotin 1.0 mg/kg 3Q4W"}],"paramType":"MEDIAN","populationDescription":"The full analysis set included all participants who received at least 1 dose of enapotamab vedotin. Participants were classified according to first dose received.","reportingStatus":"POSTED","timeFrame":"Day 1 through 44.5 months (maximum observed duration)","title":"Progression Free Survival (PFS) as Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"Months"}